Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Mitogen-activated protein kinase 14 | ||
| Ligand | BDBM50157879 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_1565897 (CHEMBL3790001) | ||
| IC50 | >10000±n/a nM | ||
| Citation |  Fairhurst, RA; Marsilje, TH; Stutz, S; Boos, A; Niklaus, M; Chen, B; Jiang, S; Lu, W; Furet, P; McCarthy, C; Stauffer, F; Guagnano, V; Vaupel, A; Michellys, PY; Schnell, C; Jeay, S Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. Bioorg Med Chem Lett26:2057-64 (2016) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Mitogen-activated protein kinase 14 | |||
| Name: | Mitogen-activated protein kinase 14 | ||
| Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 41286.76 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Q16539 | ||
| Residue: | 360 | ||
| Sequence: |
| ||
| BDBM50157879 | |||
| n/a | |||
| Name | BDBM50157879 | ||
| Synonyms: | CHEMBL1614712 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C27H29N5O | ||
| Mol. Mass. | 439.5521 | ||
| SMILES | [H][C@]1(CN2CCC2)C[C@]([H])(C1)n1cc(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc12 |wD:8.9,1.0,(6.47,-15.11,;5.71,-13.78,;4.93,-15.11,;5.69,-16.44,;5.68,-17.98,;7.22,-17.99,;7.23,-16.45,;5.31,-12.3,;6.81,-11.9,;6.02,-10.55,;7.2,-13.39,;7.59,-10.56,;6.61,-9.37,;7.45,-8.07,;7.04,-6.58,;5.56,-6.19,;5.15,-4.71,;6.24,-3.6,;7.73,-3.99,;8.81,-2.89,;10.15,-3.66,;11.48,-2.89,;12.81,-3.66,;14.12,-2.9,;14.13,-1.36,;12.8,-.59,;11.48,-1.36,;8.13,-5.47,;8.94,-8.47,;10.35,-7.7,;10.34,-6.15,;11.69,-8.46,;11.69,-10.01,;10.35,-10.79,;9.02,-10.01,)| | ||
| Structure | 
| ||